Featured Press Releases

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

Jabil acquires Pharmaceutics International, Inc

Jabil acquires Pharmaceutics International, Inc

  • 05 Feb 2025

Jabil Inc. a global leader in engineering, manufacturing, and supply chain solutions, announced...

Get visibly lifted with SkinCeuticals

Get visibly lifted with SkinCeuticals' newest lifting solution, A.G.E. Interruptor Ultra Serum for your face

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Rigaku Analytical Devices Partners with Leading Pharmaceutical Supplier

Rigaku Analytical Devices Partners with Leading Pharmaceutical Supplier

Delcath Systems Receives FDA Clearance for IND Application to Begin Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems Receives FDA Clearance for IND Application to Begin Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

  • Sprout Pharmaceuticals
  • 30 Apr 2026
Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

  • YARAL Pharma Inc.
  • 30 Apr 2026
Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

  • SQ Innovation
  • 29 Apr 2026
Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

  • Rapid Nexus
  • 29 Apr 2026
Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

  • Apertura Gene Therapy
  • 28 Apr 2026
AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

  • AbbVie
  • 28 Apr 2026
The Digital Pharma Advances Conference 2026

Most Popular
May   2026
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.